These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15857290)

  • 1. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.
    Caraglia M; Budillon A; Tagliaferri P; Marra M; Abbruzzese A; Caponigro F
    Curr Drug Targets; 2005 May; 6(3):301-23. PubMed ID: 15857290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyltransferase inhibitors.
    Hahn SM; Bernhard E; McKenna WG
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
    Baum C; Kirschmeier P
    Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
    Thomas X; Elhamri M
    Bull Cancer; 2005 Mar; 92(3):227-38. PubMed ID: 15820917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyl transferase inhibitors in the treatment of breast cancer.
    Kelland LR
    Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving therapies: farnesyltransferase inhibitors.
    Purcell WT; Donehower RC
    Curr Oncol Rep; 2002 Jan; 4(1):29-36. PubMed ID: 11734111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
    de Bono JS; Tolcher AW; Rowinsky EK
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):79-92. PubMed ID: 14613029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.
    O'Meara SJ; Kinsella BT
    Biochem J; 2005 Feb; 386(Pt 1):177-89. PubMed ID: 15469414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
    Graaf MR; Richel DJ; van Noorden CJ; Guchelaar HJ
    Cancer Treat Rev; 2004 Nov; 30(7):609-41. PubMed ID: 15531395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
    Helbig G; HoĊ‚owiecki J
    Wiad Lek; 2004; 57(9-10):462-7. PubMed ID: 15765763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein farnesyltransferase inhibitors.
    Ayral-Kaloustian S; Salaski EJ
    Curr Med Chem; 2002 May; 9(10):1003-32. PubMed ID: 12733981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of farsenyl transferase inhibitors as anticancer agents].
    Cestac P; Doisneau-Sixou S; Favre G
    Ann Pharm Fr; 2005 Jan; 63(1):76-84. PubMed ID: 15803104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesyltransferase inhibitors in breast cancer therapy.
    Dy GK; Adjei AA
    Cancer Invest; 2002; 20 Suppl 2():30-7. PubMed ID: 12442347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Farnesyl transferase inhibitors--a novel agent for breast cancer].
    Zhang M; Jiang D
    Ai Zheng; 2006 Apr; 25(4):516-20. PubMed ID: 16613692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
    Cox AD; Der CJ; Philips MR
    Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid posttranslational modifications. Farnesyl transferase inhibitors.
    Basso AD; Kirschmeier P; Bishop WR
    J Lipid Res; 2006 Jan; 47(1):15-31. PubMed ID: 16278491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyl transferase inhibitors as anticancer agents.
    Haluska P; Dy GK; Adjei AA
    Eur J Cancer; 2002 Sep; 38(13):1685-700. PubMed ID: 12175684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.